uniQure (NASDAQ:QURE) Coverage Initiated by Analysts at Chardan Capital

Chardan Capital initiated coverage on shares of uniQure (NASDAQ:QURE) in a research report sent to investors on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $38.00 price target on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on QURE. Leerink Partners raised their target price on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Stifel Nicolaus upped their target price on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. The Goldman Sachs Group lifted their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Finally, Cantor Fitzgerald upped their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $38.80.

uniQure Price Performance

NASDAQ QURE opened at $9.91 on Tuesday. The stock has a market capitalization of $535.90 million, a price-to-earnings ratio of -2.00 and a beta of 0.37. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The business’s fifty day moving average price is $13.60 and its 200-day moving average price is $10.89.

Insider Activity

In other uniQure news, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $153,448.70. Following the sale, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. The trade was a 8.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the transaction, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at $6,574,599.40. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 over the last ninety days. Corporate insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. increased its stake in uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after acquiring an additional 752,889 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of uniQure in the third quarter valued at $444,000. FMR LLC increased its position in uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Sanders Morris Harris LLC raised its stake in uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after purchasing an additional 34,034 shares in the last quarter. Finally, Franklin Resources Inc. bought a new position in uniQure during the third quarter valued at $7,360,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.